Isak Isakov
Psychiatry · Forest Hills, NYNPI 1770521775
Payments from drug & device makers
Across 1,263 payments — averaging $375.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$141K
- Otsuka America Pharmaceutical, Inc.$102K
- Neurocrine Biosciences, Inc.$75K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$48K
- Axsome Therapeutics, Inc.$34K
- Teva Pharmaceuticals USA, Inc.$22K
- plus $53K from 15 others
What the payments were for
- Consulting fees$34,4887%
- Speaking & faculty fees$388,70882%
- Travel & lodging$16,5783%
- Food & beverage$34,1337%
- Education$4900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 193 | $140,838 |
| Otsuka America Pharmaceutical, Inc. | 200 | $101,747 |
| Neurocrine Biosciences, Inc. | 186 | $74,675 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 84 | $48,180 |
| Axsome Therapeutics, Inc. | 41 | $33,937 |
| Teva Pharmaceuticals USA, Inc. | 127 | $21,620 |
| AbbVie(2 entities) | 89 | $13,925 |
| Indivior Inc. | 44 | $13,185 |
| Johnson & Johnson | 68 | $11,404 |
| E.r. Squibb & Sons, L.L.C. | 36 | $9,289 |
| Takeda Pharmaceuticals U.S.A., Inc. | 42 | $2,482 |
| Lundbeck LLC | 79 | $1,197 |
| Vanda Pharmaceuticals Inc. | 26 | $783 |
| Sunovion Pharmaceuticals Inc. | 37 | $726 |
| Janssen Scientific Affairs, LLC | 1 | $200 |
| Avanir Pharmaceuticals, Inc. | 2 | $48 |
| Braeburn Inc. | 2 | $45 |
| Noven Therapeutics, LLC | 2 | $40 |
| Acadia Pharmaceuticals Inc | 2 | $37 |
| Ironshore Pharmaceuticals Inc. | 1 | $23 |
| Validus Pharmaceuticals LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$360,702
- LYBALVI$206,237
- ARISTADA INITIO$78,185
- INGREZZA$72,340
- ABILIFY MAINTENA$70,724
- CAPLYTA$46,874
- Auvelity$33,052
- ABILIFY ASIMTUFII$31,775
- REXULTI$30,908
- UZEDY$19,117
- PERSERIS$12,535
- VRAYLAR$12,510
- SPRAVATO$10,080
- COBENFY$7,614
- TRINTELLIX$1,800
- AUSTEDO$250
- Fanapt$125
How this compares
$474,397 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 531 | $747,791 |
| IngrezzaValbenazine Tosylate | 48 | $402,469 |
| Austedo XrDeutetrabenazine | 42 | $350,140 |
| TrintellixVortioxetine Hydrobromide | 653 | $310,275 |
| Invega SustennaPaliperidone Palmitate | 86 | $290,816 |
| LatudaLurasidone Hcl | 167 | $222,311 |
| VraylarCariprazine Hcl | 146 | $209,343 |
| LybalviOlanzapine/Samidorphan Malate | 111 | $177,761 |
| AristadaAripiprazole Lauroxil | 52 | $156,183 |
| Abilify MaintenaAripiprazole | 54 | $151,574 |
| AustedoDeutetrabenazine | 20 | $148,843 |
| NamzaricMemantine Hcl/Donepezil Hcl | 266 | $148,224 |
| UzedyRisperidone | 38 | $121,491 |
| CaplytaLumateperone Tosylate | 67 | $108,833 |
| VivitrolNaltrexone Microspheres | 46 | $78,227 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena, Abilify Asimtufii | $101,747 | $962,726597 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo, Uzedy | $21,620 | $620,475100 claims |
| Alkermes, Inc.Lybalvi, Aristada, Vivitrol | $140,838 | $412,172209 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $74,675 | $402,46948 claims |
| AbbVieVraylar, Namzaric, Lexapro | $13,925 | $380,253455 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $2,482 | $310,275653 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $11,404 | $299,17999 claims |
| Sunovion Pharmaceuticals Inc.Latuda | $726 | $222,311167 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $48,180 | $108,83367 claims |
| Axsome Therapeutics, Inc.Auvelity | $33,937 | $21,91628 claims |
| E.r. Squibb & Sons, L.L.C.Abilify | $9,289 | $18,79629 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in Forest Hills
- Elyssa BarronWhite Plains$12.8M
- Mark DibuonoStaten Island$11.9M
- Ronald BrennerHempstead$11.5M
- Anton PorsteinssonRochester$7.6M
- Michael LiebowitzNew York$7.1M
- Leslie CitromePomona$5.7M
- John KaneGlen Oaks$4M
- Inna Yuryev-GolgerBrooklyn$3M
- Subhdeep VirkBuffalo$3M
- Paul EderNew York$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.